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Objective: The present study aimed to examine whether insulin resistance and oxidative
stress are associated with cognitive impairment in first-episode drug-free schizophrenia
(SZ) patients.
Methods: Ninety first-episode SZ patients and 70 healthy controls were enrolled.
Fasting insulin (FINS) and markers of oxidative stress [oxidized glutathione (GSSG),
superoxide dismutase (SOD), nitric oxide (NO) and uric acid (UA) levels] were measured
in serum before pharmacological treatment was initiated. Psychiatric symptoms and
cognitive function were assessed with the Positive and Negative Syndrome Scale
(PANSS) and MATRICS Consensus Cognitive Battery (MCCB), respectively. In addition,
the homeostatic model assessment of insulin resistance (HOMA-IR) was also studied.
Results: HOMA-IR and serum levels of GSSG and NO were significantly higher
in SZ patients than in healthy controls (P < 0.001), while the serum levels of
SOD were significantly lower than in healthy controls (P < 0.001). HOMA-IR, GSSG
and NO levels were significantly correlated to the total cognitive function scores
of the patient group (r = −0.345,−0.369,−0.444, respectively, P < 0.05). But
these factors were not co-related to the cognitive functions in the healthy control
group. And, levels of SOD, UA were not associated with the total cognitive function
scores in both the patient and the healthy control groups. NO was positively
correlated with general pathological and the total score in the PANSS, and was
negatively correlated with six cognitive domains (r = −0.316 to −0.553, P < 0.05).
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Conclusions: The levels of insulin resistance and oxidative stress are elevated, and
correlated with the severity of cognitive impairment in drug-naïve, first-episode SZ
patients. Treatment approaches targeting on reducing insulin resistance and oxidative
stress may improve cognitive function in SZ patients.
Keywords: schizophrenia, insulin resistance, oxidative stress, cognitive impairment, psychopathology
INTRODUCTION
Schizophrenia (SZ) is a chronic severe mental illness with
mainly unknown etiology, which incurs heavy burden on the
persons affected, their families and the society (1). Cognitive
impairment has been increasingly recognized as a core feature
of SZ, and is associated with reduced social functioning,
which is important for the prognosis of patients. N-methyl-D-
aspartate (NMDA) receptor hypofunction has been implicated
in pathophysiology of SZ (2). Previous studies have suggested
that cognitive impairment is related to the hypofunction of the
NMDA receptor, a type of ionic glutamate (Glu) receptor (3).
Long-term potentiation (LTP) is induced through the NMDA
receptor pathway to enhance learning and memory (4). When
the NMDA receptor is over-activated, it causes excitatory toxicity
to neural cells, leading to cell damage and death. Moreover, the
proper function of the NMDA channel in the central nervous
systems has been reported to be regulated by many other
factors (5, 6).
Insulin resistance (IR) refers to the decreased efficiency of
insulin in the promotion of glucose uptake and use. Insulin have
effect on brain function, as it regulates the activity of NMDA and
improves synaptic plasticity (7). When the biological efficacy of
insulin decreases, the learning andmemory function are reduced.
Chen et al. believed that IR seems to play a role in cognitive
impairment in SZ (8). Studies have found that increased IR may
occur earlier in first-episode SZ patients than in healthy controls
(9). Ringen (10) also proposed that IR has been associated
with SZ.
Studies have found that the levels of oxidized products
such as GSSG and NO are increased, and the levels of
antioxidant products such as SOD are decreased in patients
with schizophrenia (11), and such changes are associated with
cognitive function and psychopathology (12). Studies have
shown that that oxidative stress causes cognitive impairment
by damaging neurons (13). The excitatory amino acid Glu and
NMDA receptors are closely related to oxidative stress, which
may cause cognitive impairment through the Glu-NMDAR-
NO pathway (14). Glu can activate NMDA receptors (15),
and produce excessive oxide and nitric oxide (NO), leading
to neuronal excitotoxicity involved in the development of
various neuropsychiatric diseases (16). Oxidative stress may be
an intermediary mechanism of NMDA receptor dysfunction
involved in the occurrence of schizophrenia. Boskovic suggested
that oxidative stress may be involved in the occurrence and
development of SZ (17). UA scavenges singlet oxygen and free
radicals, and it can also trap peroxynitrite anions (free radicals in
the ONOO –), thereby reduce the damage mediated by ONOO–.
Thus, UA is an effective neuroprotective compounds (18). In
addition, serum levels of UA can indicate the oxidative stress state
of the body. Houlihan et al. (19) studied that UA at a high level
may improve memory-related behaviors in cognitive function.
However, there is no definitive conclusion on the relationship
between UA and cognitive function.
Previous studies have reported an associations between IR,
oxidative stress and the risk of type 2 diabetes (20, 21), but there
has been little research on the associations between IR, oxidative
stress and SZ. In addition, several lines of evidence showed that
the antioxidant defense system may be disrupted in SZ patients,
and excessive free radical production and oxidative stress damage
response may be involved in the pathogenesis of SZ (22–24). Few
studies have focused on the association between IR, oxidative
stress and cognitive function in SZ patients.
The present study was to investigate if serum levels of
biomarkers reflecting IR and oxidative stress are elevated
in patients with drug-naïve, first episode SZ, and whether




All subjects in this study were approved by the Ethics Committee
of the First Affiliated Hospital of Zhengzhou University and
provided written informed consent. Inpatients 18 and 45
years old diagnosed with first-episode SZ (disease duration
<2 years) were recruited. The inclusion criteria for patients
were: (1) diagnosis of first episode SZ based on the Diagnostic
and Statistical Manual of Mental Disorders fourth version
(DSM-IV) criteria and confirmed using the Structured Clinical
Interview for DSM-IV (SCID) (25); (2) never treated with
antipsychotic medications or other psychotropics; (3) the PANSS
total score >60 points. Exclusion criteria included: (1) diagnose
neurological or other mental illnesses, autoimmune diseases,
diabetes and other organic diseases; (2) alcohol or substance
abuse history; (3) pregnant or lactating women; (4) have taken
any antibiotics, anti-inflammatory agents or probiotics in the
past month; (5) major changes in living environment or diet in
the past month. Recruitment of normal-weight healthy control
subjects through advertisement, they had the same exclusion
criteria as the patient group; Moreover, none of them had a
history of any psychiatric diseases.
Assessments
The psychiatric symptoms of SZ were assessed in all enrolled
patients using the Positive and Negative Syndrome Scale
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(PANSS) (26). The PANSS was administered by a professionally
trained and experienced psychiatrist. All subjects received a
baseline cognitive evaluation using the MATRICS Consensus
Cognitive Battery (MCCB) (27). It involves seven cognitive areas:
(1) Speed of Processing Information; (2) Attention and Vigilance
Awareness; (3) Working Memory; (4): Verbal Learning; (5)
Visual Learning; (6) Reasoning and Problem Solving; (7) Social
Cognition. The MCCB scoring program generates T-scores
that are standardized and corrected for age and sex (27). The
“cognitive composite” is the standardized sum of the seven
domains. Training, data collection and data quality assurance
were implemented or supervised by experienced psychologists
in accordance with the guidelines outlined in the MCCB
manual (27).
Biochemical Measurements
After all subjects were enrolled, 5ml of venous blood was
collected from the elbow under fasting condition (12 h fasting)
by full-time laboratory personnel in the morning of the next
day from 6:30 a.m. to 7:30 a.m. to avoid the influence of
biological rhythm changes of the measured factors. Venous
blood samples were collected from the elbows into EDTA
anticoagulant tubes at 4◦C for 10min at 3,000 r/rain to
separate the upper serum. FPG levels were measured by the
glucose oxidase method and an automated analyzer (Roche
Diagnostics, C8000, Germany), serum FINS levels weremeasured
by radioimmunoassay (Elecsys 2010, Roche, Basel, Switzerland);
GSSG was measured by a microenzyme method (A061-1,China);
Serum SOD levels was measured using the kits and Roche
automatic biochemical analyzer (Roche Diagnostics, C8000,
Germany); NO levels was detected by one-step method (A013-
2,China); The serum uric acid (UA)levels was measured by
uricase-peroxidase method (Roche, C720, Switzerland). The
current group of non-smokers had never smoked before. The
homeostasis model of assessment of insulin resistance (HOMA-
IR) was calculated using the following formula: HOMA-IR =
FPG (mmol/L)× FINS (mu/L)/22.5 (28). Bodymass index (BMI)
= height/body mass ² (kg/m ²).
Statistical Analysis
SPSS 21.0 statistical software was used for all data analysis.
All numeric variables data were expressed as mean ±SD.
All categorical variables data were expressed as ratios and
frequencies. Group comparison was performed using an
unpaired t-test, and Chi-square test was used for testing
independence among categorical variables. The correlations
between IR, oxidative stress and cognitive function was
computed by Pearson’s correlation. two-sided P < 0.05 indicated
that the difference was statistically significant.
RESULTS
Table 1 shows that there were no significant differences in age,
education, gender, smoking status, and BMI between the SZ
patients and healthy control groups (P > 0.05). In the seven
domains of cognitive function, the scores of the SZ patient group
were significantly lower than those of the healthy control group
(P < 0.05, Table 1).
Table 2 shows that FPG levels in SZ patients showed an
increased trend but fell short of statistical significance (t = 1.448,
P = 0.150); However, FINS, HOMA-IR, GSSG, and NO levels
were higher in the SZ patients than in the healthy controls (P
< 0.001). On the other hand, the serum SOD levels were lower
in the SZ patients than in the healthy controls (t = −3.703,
P < 0.001).
Table 3 shows that HOMA-IR, GSSG and NO were
significantly correlated to the total cognitive function scores of
the patient group (r = −0.345, −0.369, −0.444, respectively,
P < 0.05, Table 3). In a multiple regressing model including
HOMA-IR, GSSG, NO as predictors, and the total MCCB score
as the dependent variable, we found that only HOMA-IR had an
effect on the MCCB composite score (t =−2.321, P < 0.05).
Table 4 shows that within the patient groups, the NO levels
were positively correlated with the general pathological score
and total score in the PANSS assessment (r = 0.323,0.375,
respectively, P < 0.05, Table 4). After controlling for age,
gender, disease duration and smoking status, we found that
these biological indicators (FINS, HOMA-IR, GSSG, NO, SOD,
UA) showed no correlation with the scores of PANSS (positive
symptom score, negative symptom score, general pathology
score, and PANSS total score) (P > 0.001).
DISCUSSION
Previous studies have reported associations between IR, oxidative
stress and the risk of type 2 diabetes (20), but there has been
little research on the associations between IR, oxidative stress
and SZ. In addition, few studies have focused on the association
between IR, oxidative stress and cognitive function in SZ patients.
Our study found that serum marker levels for insulin resistance
and oxidative stress were increased compared to healthy controls
in first-episode untreated SZ patients, and that the levels were
associated with cognitive function impairment. We also found
correlations between several indicators of oxidative stress and
clinical symptoms in the SZ patient group. To our knowledge, the
present study is the first to show associations between cognitive
performance and markers of IR and oxidative stress in first-
episode untreated SZ patients.
Serum FINS and HOMA-IR were increased in first-
episode SZ patients, consistent with the previous study by
Spelman (9). Other published studies have shown that the
development of IR may be caused by decreased insulin tyrosine
kinase receptor activity, abnormal insulin signaling, decreased
glucose transportation, decreased glucose phosphorylation and
decreased glycogen synthase activity (29). As a result of IR,
the activity of the cholinergic system in the hippocampus and
other brain regions is significantly decreased, which can lead
to neuronal degeneration and aggravated cognitive impairment.
Our results showed that FINS levels and HOMA-IR were
positively correlated with the severity of cognitive impairment in
SZ patients. This effect may be related to the following aspects:
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TABLE 1 | Demographic and clinical characteristics of the study sample.
Patients Healthy controls Group comparison
Characteristics N = 90 N = 70
Mean (SD) Mean (SD) t/χ2 p
Age (years) 21.5 ± 7.7 23.4 ± 5.4 −1.592 0.114
Education (years) 10.4 ± 2.6 11.1 ± 2.4 −1.63 0.106
BMI (kg/m2 ) 21.5 ± 2.2 21.1 ± 2.4 1.052 0.295
Disease duration (months) 5.9 ± 6.3
N (%) N (%)
Gender −0.397 0.692
Male 44 (48.9) 32 (45.7)
Female 46 (51.1) 38 (54.3)
Smoking status 1.056 0.293
Yes 5 (0.06) 7 (0.10)
No 85 (0.94) 63 (0.90)
PANSS-total 84.2 ± 12.7
PANSS-positive 23.2 ± 4.8
PANSS-negative 22.4 ± 5.9
PANSS-general 38.5 ± 7.8
MCCB composite score 28.6 ± 16.5 45.1 ± 19.4 −5.790 0.000
SOP 30.6 ± 9.4 51.7 ± 10.0 −12,334 0.000
CPT-IP 32.5 ± 10.9 50.7 ± 9.2 −10.201 0.000
WMS-III 38.8 ± 9.4 55.6 ± 10.6 −9.632 0.000
HVLT 37.6 ± 7.6 50.7 ± 10.0 −8.465 0.000
BVMT 39.8 ± 10.1 57.2 ± 12.1 −8.925 0.000
NAB 40.1 ± 9.8 46.1 ± 10.5 −3.351 0.001
MSCEIT 39.0 ± 11.6 56.3 ± 15.1 −7.375 0.000
PANSS-positive, Positive Symptom; PANSS-negative, Negative Symptom; PANSS-general, General Pathological Score; PANSS-total, PANSS Total Score.
TABLE 2 | Comparison of insulin resistance and oxidative stress measures between the two groups.
Patient group Healthy control group t P
Items (N = 90) (N = 70)
BIOCHEMICAL MEASURES
FPG (mmol/L) 4.4 ± 0.5 4.3 ± 0.7 1.448 0.150
FINS (mmol/L) 11.1 ± 3.3 6.1 ± 1.1 10.338 0.000
HOMA-IR (mU/L) 2.2 ± 0.7 1.2 ± 0.3 10.790 0.000
GSSG 30.9 ± 7.6 16.8 ± 5.8 11.667 0.000
NO 103.9 ± 54.5 32.2 ± 33.6 8.839 0.000
SOD 198.6 ± 43.1 231.7 ± 29.1 −3.703 0.000
UA 292.2 ± 87.5 273.6 ± 60.1 1.303 0.195
FPG, fasting plasma glucose; FINS, fasting insulin; HOMA-IR, insulin resistance index; GSSG, oxidized glutathione; NO, nitric oxide; SOD, superoxide dismutase; UA, uric acid.
(1) IR may be accompanied by insulin-like growth factor-1 (IGF-
1) resistance, which competitively inhibits the binding of insulin
to the insulin receptor (30). Other studies have reported elevated
plasma FINS levels and decreased IGF-1 in SZ patients (31). (2)
High FINS levels can disturb the insulin signaling pathway and
decrease metalloproteinase (IDE) levels, leading to intracellular
and extracellular Amyloid- β deposition, and causing neuronal
degeneration. (3) IR can promote neuronal inflammation by
enhancing the release of pro-inflammatory cytokines such as
IL-1α, IL-1β, IL-6, and TNF-α. (4) Long-term IR can increase the
content of highly active oxidative groups and decrease the activity
of antioxidant enzymes, causing neuronal cell apoptosis (32).
In the present study, we found that the levels of oxidized
products (GSSG, and NO) were significantly increased in SZ
patients, while SOD levels were significantly decreased, and that
these levels were correlated to some cognitive function domains.
Numerous studies have revealed an imbalance between the
oxidative and antioxidant systems in SZ patients (33). Evidenced
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TABLE 3 | Insulin resistance, oxidative stress, and cognitive function.
Indicators HOMA-IR GSSG NO SOD UA
r P r P r P r P r P
MCCB composite −0.345 0.001 −0.369 0.003 −0.444 0.000 0.200 0.143 −0.113 0.350
score (Patient group)
MCCB composite score 0.020 0.891 −0.153 0.230 0.001 0.997 0.002 0.992 0.118 0.412
(Healthy control group)
TABLE 4 | Correlation of FINS, HOMA-IR, GSSG, NO, SOD, and UA values with PANSS in patient group (N = 90).
Indicators FINS HOMA-IR GSSG NO SOD UA
r P r P r P r P r P r P
PANSS-positive 0.041 0.763 0.146 0.283 0.119 0.401 0.159 0.260 −0.081 0.591 −0.191 0.176
PANSS-negative 0.012 0.930 0.020 0.886 −0.082 0.562 0.213 0.130 −0.125 0.409 0.012 0.931
PANSS-general 0.078 0.568 0.013 0.924 0.011 0.936 0.323 0.020 0.024 0.874 −0.142 0.317
PANSS-total 0.065 0.636 0.059 0.663 0.016 0.908 0.375 0.006 −0.083 0.585 −0.138 0.331
by increased GSSG and NO levels accompanied by decreased
SOD levels (34), and such an imbalance may correlate with
impaired cognitive functions (12). NO, as a signaling molecule,
may be involved in the impairment of cognitive function in SZ
patients through the following mechanisms: (1) activation of
the hypothalamus- pituitary-adrenal axis, secretion of prolactin,
and corticosteroids, and elevation of hormones levels and thus
activating the dopaminergic neurons in the hypothalamus,
causing positive symptoms and cognitive impairment (35); (2)
NMDA receptor activation, which is involved in the release of
Glu and dopamine, and causes cognitive deficits and mental
disorders (36); and (3) reduction in nitrite ions and superoxide
anions, which react to the formation of peroxynitrite anions,
leading to neurotoxic effects.
Previous studies have suggested that the antioxidant defense
system is disrupted in SZ patients, and excessive free radical
production and oxidative stress damage response may be
involved in the pathogenesis of SZ (22, 23). SOD and UA are
both effective indicators of antioxidant capacity, and SOD as an
enzyme can effectively scavenge oxygen free radicals in the body,
representing an important component of the free radical defense
system. Our results showed that SOD levels were significantly
decreased in SZ patients compared with healthy control subjects,
which was consistent with the study by Reyazuddin (37),
indicating that there may be a high level of oxidative stress in SZ
patients. Other studies noted that the presence of the oxidative
stress indicators SOD and NO in first-episode SZ patients is
associated with cognitive impairment, consistent with the results
of the present study. Our study did not find a correlation
between UA levels and cognitive function impairment in SZ
patients. whether SZ patients have a lower level of UA remains
controversial (38–40).
Hyperglycemia, which mediates oxidative stress by directly
or indirectly activating the diacylglycerol (DAG) -PKC pathway,
is the main source of oxidative stress (41). Studies have shown
that the PKC-D subtype is a potential activator of nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase, and the
activation of NADPH oxidase can increase the production of
reactive oxygen species(ROS) (42). Normally, insulin receptor
substrates (IRS-1 and IRS-2) are mainly distributed in low
density microsomes (LDMs). However, but upon activating
these receptors, phosphatidylinositol 3-kinase (P13K) is recruited
to LDMs (43). Oxidative stress can interfere with P13K
migration from the cytoplasm to LDMs, thereby inducing
IR. Thus, oxidative stress reduces the recruitment of P13K
by interfering with the phosphorylation of insulin receptor
substrates, thereby inducing IR. On the other hand, High
levels of free fatty acids lead to an increase in ROS and
reactive nitrogen species (RNS), thereby activating the oxidative
stress mechanisms that damage DNA, proteins and lipids.
Additionally, high levels of free fatty acids can activate a
range of intracellular signaling pathways that are closely related
to IR and other cellular functions. The dysregulation of free
fatty acids leads to neurodegenerative disease by promoting
the phosphorylation of tau in the hippocampus (44). Insulin
inhibits the activity of glycogen synthesis kinase-3β (GSK-
3β), which phosphorylates tau, pyruvate dehydrogenase, and
glycogen synthase. GSK-3β activation under insulin deficiency
or IR promotes the phosphorylation of tau and the inactivation
of pyruvate dehydrogenase and glycogen, affecting energy
metabolism and acetylcholine synthesis. Thus, the interplay
between IR and oxidative stress factors can synergistically impair
cognitive functions in the SZ patients (45).
This study has several advantages. Our results were based
on a relatively large number of drug-naïve SZ patients. The
status of being drug-naïve and first episodes are important
in removing the impact of medications on the associations
between IR and oxidative stress and cognitive impairment in SZ
patients. However, the present study also has limitations. Our
results were based on analysis of cross-sectional samples. Future
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follow-up studies that have measurements at multiple time
points may strengthen our conclusions. In addition, unmeasured
confounders in the present study may have some impact on our
results thus future replication studies are warranted.
In summary, in the present work, we report abnormal
IR and oxidative stress factors in first-episode untreated
SZ patients, and show how they are correlated to on
cognitive function. There was an association between IR and
oxidative stress in the patients. The current findings need
to be replicate, but suggest that IR may be a peripheral
biological marker of cognitive dysfunction development in
SZ patients, and could play a role in the pathological
disease processes.
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